Articles

Patient-specific doses of iodine-131-apamistamab resulted in consistent engraftment following allogeneic hematopoietic stem-cell transplantation among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Read More ›

Patients with FLT3 mutation–positive R/R AML who relapsed on gilteritinib therapy were found to have acquired new mutations that were not present at baseline. The most common mutations occurred in RAS/MAPK pathway genes and FLT3.Patients with mutations in RAS/MAPK pathway genes at baseline still benefited from gilteritinib therapy. Read More ›

The efficacy of LDAC plus quizartinib versus LDAC alone in patients aged ≥60 years unable to undergo intensive therapy was assessed. Although addition of quizartinib to LDAC did not result in improved survival for the study population, it did improve survival for the FLT3- ITD patient subgroup. Read More ›

Selinexor in combination with standard induction and consolidation therapy appears highly active in older patients with de novo acute myeloid leukemia. Read More ›

This first-in-human study indicates that CLL1-CD33 cCAR has favorable efficacy and manageable toxicity in patients with R/R AML. Read More ›

The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V⁶⁰⁰-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read More ›

The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read More ›

A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read More ›

In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read More ›

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›